Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

available-for-sale totaled $61.7 million.

Recent Highlights

-- IND Accepted for ANA773. During the third quarter, Anadys filed an

Investigational New Drug Application (IND) to commence the clinical

investigation of ANA773 in cancer patients. The Food and Drug

Administration has accepted our IND and we expect to begin our first

clinical trial of ANA773 by the end of the year. ANA773, a novel oral

prodrug of a TLR7 agonist, has demonstrated favorable biologic activity

and promising pharmaceutical properties in preclinical studies.

-- Appointment of Steve Worland, Ph.D. as President and CEO. On

August 24, 2007, we announced that Steve Worland, Ph.D. had been

promoted to the position of President and Chief Executive Officer. Dr.

Worland was also appointed as a member of the Company's Board of

Directors. Dr. Worland joined Anadys in March 2001 as Chief Scientific

Officer and most recently served as President, Pharmaceuticals. Prior

to joining the Company, Dr. Worland was Vice President, Head of

Antiviral Research, at Agouron Pharmaceuticals, a Pfizer Company and

was also a Vice President at Warner-Lambert prior to its acquisition by

Pfizer.

-- Discontinuation of ANA975 Development and Strategic Restructuring of

Company. On July 26, 2007, Anadys announced that it and its

collaborator Novartis had decided to discontinue the development of

ANA975, a phase 1b compound for the treatment of hepatitis C virus

(HCV) infection. Following this decision, Anadys has undertaken a

strategic restructuring to focus its resources on the development of

ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B

polymerase for the treatment of HCV, and ANA773, an oral TLR7 agonist

prodrug for the treatment of certain cancers. Included within this<
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... TRIANGLE PARK, N.C., Nov. 17, 2010 Chimerix, Inc., ... an update to the World Health Organization (WHO) on ... at the 12th Meeting of the WHO Advisory Committee ... of CMX001 for Smallpox and Other dsDNA Viruses."  CMX001 ...
... AVANIR Pharmaceuticals, Inc. (Nasdaq: ... sell shares of its common stock in an underwritten public ... manager in the offering and Canaccord Genuity Inc., Wedbush PacGrow ... acting as co-managers for the offering.  In addition Trout Capital ...
... 2010 Imagenetix, Inc. (OTC Bulletin Board: IAGX ... ended September 30, 2010. Net sales increased 69% for the ... for the same period of last year.  Net income for ... net income of $553,000, $.05 per share, for the same ...
Cached Biology Technology:Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 3AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Imagenetix, Inc. Reports Second Quarter 2011 Results 2Imagenetix, Inc. Reports Second Quarter 2011 Results 3
(Date:4/20/2014)... with Down syndrome have a heightened risk of developing ... able to explain why. Now, a team of ... the two conditions. , In a study posted online ... researchers track the genetic chain of events that links ... havoc that occurs in ALL. Their findings are ...
(Date:4/18/2014)... For the past 20 years, researchers have published ... research findings have suggested that soil organic carbon can ... tillage systems to no-till systems. However, there is a ... in corn and soybean rotations without cover crops, small ... carbon stocks at the published rates. , "Some studies ...
(Date:4/17/2014)... In the most densely forested and most densely populated ... of human needs, values and practices. Disturbances associated with ... agriculture and development, have set the stage for management ... study reports. , The report Five anthropogenic factors ... in the Northern United States was published ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... massive changes to the Earth's landscape , The ice ages ... happening below the ice in the oceans? , Research by ... destruction as whole communities of animals were wiped out by ... it has been thought that these ecosystems somehow dodged extinction ...
... at the Naval Research Laboratory's Marine Meteorology Division ... Monterey Bay Aquarium Research Institute and the National ... of a phenomenon known as the "milky sea." ... ship-based account. This research was published in the ...
... Wright Brothers' first biplanes to monoplanes was an inadvertent ... say two dino flight experts. , According to ... a small early Chinese dinosaur called Microraptor gui used ... to tree in the early Cretaceous. Among the evidence ...
Cached Biology News:Seafloor creatures destroyed by ice action during ice ages 2NRL scientists detect 'milky sea' phenomena 2NRL scientists detect 'milky sea' phenomena 3Wright bros. upstaged! Dinos invented biplanes 2Wright bros. upstaged! Dinos invented biplanes 3
Request Info...
... the membrane-permeant ester forms (CCF2-AM and ... beta-lactamase substrates, CCF2 and CCF4. These ... where cleavage by endogeneous cytoplasmic esterases ... charged forms, thereby trapping them in ...
Chlorine-36, 3.7 MBq, 100 uCi. 0.1-0.3 HCl.< 111 MBq/g Cl, < 3 mCi/g Cl.Dispensed to order. Please inquire for alternative pack sizes. Category: Radiochemicals &Radiation Safety, Radiochemicals....
Src cDNA Expression Kit (wild type)...
Biology Products: